Natural Progression of Canine Glycogen Storage Disease Type IIIa.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Comparative medicine

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 26884409PMCID PMC4752035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correction of glycogen storage disease type III with rapamycin in a canine model

  2014cited by this paper
• Mouse model of glycogen storage disease type III.

  2014cited by this paper
• Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.

  2014cited by this paper
• Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study

  2013cited by this paper
• The emerging phenotype of long-term survivors with infantile Pompe disease

  2012cited by this paper
• Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases.

  2012cited by this paper
• Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa.

  2012cited by this paper
• Cardiac Pathology in Glycogen Storage Disease Type III.

  2012cited by this paper
• Characterization of a canine model of glycogen storage disease type IIIa

  2012cited by this paper
• Successful Treatment of Severe Cardiomyopathy in Glycogen Storage Disease Type III With D,L-3-Hydroxybutyrate, Ketogenic and High-Protein Diet

  2011cited by this paper
• Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient.

  2011cited by this paper
• Stone forming risk factors in patients with type Ia glycogen storage disease.

  2010cited by this paper
• Glycogen Storage Disease Type III diagnosis and management guidelines

  2010cited by this paper
• Glycogen Storage Disease Type 1: Impact of Medium-Chain Triglycerides on Metabolic Control and Growth

  2010cited by this paper
• Investigating glycogenosis type III patients with multi-parametric functional NMR imaging and spectroscopy.

  2010cited by this paper
• The electrodiagnostic characteristics of Glycogen Storage Disease Type III

  2010cited by this paper
• Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet

  2009cited by this paper
• Glycogen storage disease type IIIa in curly-coated retrievers.

  2007cited by this paper
• Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?

  2007cited by this paper
• Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk

  2007cited by this paper
• Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency.

  2007cited by this paper
• [Type III glycogen storage disease associated with hepatocellular carcinoma].

  2005cited by this paper
• Glucogenosis tipo III asociada a carcinoma hepatocelular

  2005cited by this paper
• Type I glycogen storage disease: Kidney involvement, pathogenesis and its treatment

  2004cited by this paper
• Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX

  2004cited by this paper
• Canine Model and Genomic Structural Organization of Glycogen Storage Disease Type Ia (GSD Ia)

  2001cited by this paper
• The utility of AST/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis.

  2000cited by this paper
• Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.

  2000cited by this paper
• Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease.

  2000cited by this paper
• The age dependent levels of serum ALP isoenzymes and the diagnostic significance of corticosteroid-induced ALP during long-term glucocorticoid treatment.

  1997cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism

  1995cited by this paper
• Glycogen Storage Disease in Adults

  1994cited by this paper
• Glycogen debranching enzyme deficiency: Long-term study of serum enzyme activities and clinical features

  1992cited by this paper
• Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.

  1990cited by this paper
• Accumulation of glycogen in sural nerve axons in adult‐onset type III glycogenosis

  1986cited by this paper
• Peripheral nerve in type III glycogenosis: Selective involvement of unmyelinated fiber schwann cells

  1985cited by this paper
• Debrancher deficiency: Neuromuscular disorder in 5 adults

  1979cited by this paper
• Miller's anatomy of the dog

  1979cited by this paper
• Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry.

  1976cited by this paper

• Long‐Term Correction of Murine Glycogen Storage Disease Type III by AAV‐Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase

  2025cites this paper
• Galectin-3: a novel biomarker of glycogen storage disease type III

  2025cites this paper
• Cell Modeling and Rescue of a Novel Non-coding Genetic Cause of Glycogen Storage Disease IX

  2025cites this paper
• Progressive liver disease and dysregulated glycogen metabolism in murine GSD IX γ2 models human disease.

  2024cites this paper
• Gene therapy for glycogen storage diseases

  2023influential citation
• Biomarkers in Glycogen Storage Diseases: An Update

  2021cites this paper
• A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

  2021cites this paper
• Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III

  2020cites this paper
• A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme

  2020cites this paper
• Response to Heiner-Fokkema et al.

  2020cites this paper
• Glycogen storage disease type VI can progress to cirrhosis: ten Chinese patients with GSD VI and a literature review

  2020cites this paper
• Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models

  2020influential citation
• Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects

  2020cites this paper
• Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring

  2019influential citation
• The Dog Model in the Spotlight: Legacy of a Trustful Cooperation

  2019cites this paper
• Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III

  2019cites this paper
• Preclinical Gene Therapy Studies for Metabolic Myopathy

  2019cites this paper
• Hepatic Manifestations in Glycogen Storage Disease Type III

  2018cites this paper
• Neuromuscular Involvement in Glycogen Storage Disease Type III in Fifty Tunisian Patients: Phenotype and Natural History in Young Patients

  2018cites this paper
• Clinical, biochemical and genetic aspects of glycogen storage disease type III

  2017cites this paper